Acute Myeloid Leukaemia patients given a new type of smart drug in addition to chemotherapy treatment are 22 percent less likely to relapse and around 13 percent less likely to die from their disease, according to a study released today.
The results from the major phase III Cancer Research UK-funded trial led by Cardiff University and trialled by 1,115 patients, found that 68 percent of people relapsed on the new treatment within three years, compared with 76 percent of those who had only had the standard treatment.
25 percent of those tested were still alive after three years, compared with 20 per cent of those who had the standard treatment.
The drug - called Gemtuzumab Ozogamicin (GO)* - is part of a new class of antibody conjugate drugs, which involve attaching chemotherapy molecules to antibodies.
More top news
Drivers of the most polluting vehicles will pay the new £10 T-Charge, meaning a daily payment of £21.50 to enter central London.
It is estimated there are 50,000 alcohol-related hospital admissions a year, costing the Welsh NHS £120m annually.
A rather cloudy start for most, with rain spreading eastwards, clearing to brighter skies later in the day.